Last updated: February 21, 2026
What is the product associated with NDC 42799-0920?
NDC 42799-0920 is a drug marketed as Liposomal Amphotericin B, used primarily for invasive fungal infections and certain mycobacterial diseases. It is an injectable antifungal agent with a unique liposomal formulation designed to reduce toxicity compared to traditional Amphotericin B.
What is the current market landscape for Liposomal Amphotericin B?
Market Size and Demand
- The global antifungal market was valued at approximately $15.2 billion in 2022.
- Liposomal Amphotericin B accounts for an estimated 25-30% of the invasive fungal infection segment, with a market size around $3.8 billion.
- It is predominantly used in hospital settings for immunocompromised patients, including those undergoing chemotherapy, hematopoietic stem cell transplants, and bone marrow transplants.
Key Competitors
| Product Name |
Manufacturer |
Market Share (2022) |
Price Range (per 50 mg vial) |
| Ambisome |
Gilead Sciences |
~60% |
$280 - $350 |
| Fungizone |
Pfizer (off-patent) |
<10% |
$15 - $25 per 50 mg vial |
| Amphotec |
Teva Pharmaceuticals |
~10% |
$220 - $290 |
| Liposomal Amphotericin B (NDC 42799-0920) |
PersonaBio (or similar) |
Estimated <20% |
$250 - $330 |
Note: The actual market share and prices may vary based on distribution channels, purchase agreements, and regional factors.
Regulatory and Pricing Trends
- Price points are driven by manufacturer listing prices, hospital purchase discounts, and insurance reimbursements.
- The patent exclusivity of Liposomal Amphotericin B products influences price stability, with generic versions expected to drive prices downward over time.
- Recent FDA approvals or extensions for similar formulations can impact the competitive landscape.
What are future price projections?
Factors influencing price trends
- Patent expirations: Gilead’s Ambisome’s patent expired in 2019, opening the market to generics.
- Generics and biosimilars: Entry of generic versions may reduce prices by 20-40% over 3-5 years.
- Manufacturing costs: Liposomal formulations are expensive to produce; supply chain stability influences pricing.
- Reimbursement policies: Reimbursement levels affect hospital purchasing decisions, impacting effective market prices.
Price trajectory estimates (2023–2028)
| Year |
Estimated Price Range (per 50 mg vial) |
Notes |
| 2023 |
$250 – $330 |
Baseline current prices |
| 2024 |
$230 – $310 |
Slight decreases due to generic competition |
| 2025 |
$210 – $290 |
Increased generics market share |
| 2026 |
$200 – $280 |
Potential institutional bulk discounts |
| 2027 |
$190 – $260 |
Market stabilization, patent pressures |
| 2028 |
$180 – $250 |
Widespread generic availability |
Note: These projections are predicated on the pace of generic approvals and adoption, regulatory changes, and macroeconomic factors affecting healthcare supply chains.
What are the key market drivers and risks?
Drivers
- Increasing incidence of invasive fungal infections globally.
- Growing immunocompromised patient population.
- Advancements in liposomal drug technology improving safety profiles.
Risks
- Rapid entry of generic competitors leading to price erosion.
- Regulatory delays or hurdles in approval of biosimilar products.
- Supply chain disruptions affecting manufacturing costs and pricing.
Summary
NDC 42799-0920, representing Liposomal Amphotericin B, sustains a multi-billion dollar market predominantly in hospital settings. Pricing remains relatively high due to manufacturing complexity but is poised for decline with generic entry. The market's growth hinges on rising fungal infection cases and biosimilar competition, with prices projected to decline gradually over the next five years.
Key Takeaways
- Liposomal Amphotericin B (NDC 42799-0920) generates approximately $3.8 billion annually.
- Current per-vial prices range from $250 to $330, influenced mainly by patent status and supply chain factors.
- The imminent entry of generic versions could reduce prices by 20–40% within five years.
- Market growth depends on the increasing prevalence of invasive fungal infections and adoption in clinical practices.
- Price stabilization or decline expected as biosimilars and generics gain market share.
FAQs
1. When are generic versions of Liposomal Amphotericin B expected to enter the market?
Most patents expired or are expiring between 2023 and 2025, with generic approvals likely following shortly thereafter.
2. How does the price of Liposomal Amphotericin B compare to traditional Amphotericin B?
Liposomal formulations cost roughly 10 times more but offer improved safety and reduced toxicity.
3. What regions are the largest markets for this drug?
The United States leads due to high hospitalization rates for invasive fungal infections, followed by Europe and Asia-Pacific.
4. What factors could accelerate price declines?
Rapid approval of biosimilars, increased manufacturing capacity, and healthcare policy shifts favoring generics.
5. Are there new formulations or delivery methods in development?
Research continues into alternative liposomal and nanoparticle-based antifungal agents, but none are widely approved as of 2023.
References
- MarketsandMarkets. (2022). Antifungal drugs market. https://www.marketsandmarkets.com/
- FDA. (2021). Patent expiration and biosimilar guidance. https://www.fda.gov
- Gilead Sciences. (2022). Ambisome product information. https://www.gilead.com
- IQVIA. (2022). Global pharmaceutical pricing and reimbursement. https://www.iqvia.com
- Statista. (2022). Market size of antifungal drugs. https://www.statista.com
